Call for clarity in the reporting of benefit associated with anticancer therapies.
Booth
Christopher M
CM
Ohorodnyk
Pavlo
P
Eisenhauer
Elizabeth A
EA
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D035081:Editorial Policies; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality; D010506:Periodicals as Topic; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D017749:Total Quality Management; D016896:Treatment Outcome; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D003841:Deoxycytidine; D005472:Fluorouracil; D000093542:Gemcitabine